or Try an Advanced Search...

    Technical Analysis for PHAT - Phathom Pharmaceuticals, Inc.

    Grade Last Price % Change Price Change
    C 10.81 4.95% 0.51
    PHAT closed up 4.95 percent on Monday, July 1, 2024, on approximately normal volume. It was able to find support at its 50 day moving average.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Up Down
    Historical PHAT trend table...
    Date Alert Name Type % Chg
    50 DMA Support Bullish 0.00%
    Crossed Above 20 DMA Bullish 0.00%
    Multiple of Ten Bullish Other 0.00%
    Outside Day Range Expansion 0.00%
    50 DMA Support Bullish 4.95%
    50 DMA Support Bullish 3.94%
    Hammer Candlestick Bullish 3.94%
    Multiple of Ten Bullish Other 3.94%
    Outside Day Range Expansion 3.94%
    50 DMA Support Bullish 5.77%
    Older End-of-Day Signals for PHAT ...

       Recent Intraday Alerts

    Alert Time
    Rose Above 20 DMA about 5 hours ago
    Up 5% about 5 hours ago
    Rose Above Previous Day's High about 7 hours ago
    Outside Day about 7 hours ago
    Up 3% about 7 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    PHAT Chart by TradingView
    Basic chart:

    Profile

    Phathom Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. It develops Vonoprazan, a potassium-competitive acid blocker. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Buffalo Grove, IL.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Life Sciences Acid Natural Sciences Medication Gastrointestinal Disorders Potassium Gastrointestinal Disease Tadataka Yamada

    Is PHAT a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 2 bullish, 0 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jun 26 Phathom Pharmaceuticals: Time To Deliver Promise Of Voquezna After Frustrating Delays
    Jun 9 Ready for Quick Gains? 7 Top Short-Squeeze Stocks to Watch Now
    Jun 7 Ride the Gamma Wave: 3 Stocks on the Verge of a Short Squeeze
    May 28 Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
    May 15 Phathom Pharmaceuticals to Present VOQUEZNA® (vonoprazan) Data at DDW 2024 Annual Meeting
    May 13 Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q1 2024 Earnings Call Transcript
    May 11 Phathom Pharmaceuticals, Inc. (PHAT) Q1 2024 Earnings Call Transcript
    May 10 The 3 Best Healthcare Stocks to Buy in May 2024
    May 9 Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Lags Revenue Estimates
    May 9 Phathom Pharmaceuticals Non-GAAP EPS of -$1.11 beats by $0.06, revenue of $1.91M misses by $0.23M
    See more PHAT news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 17.0
    52 Week Low 6.065
    Average Volume 545,184
    200-Day Moving Average 9.27
    50-Day Moving Average 10.25
    20-Day Moving Average 10.78
    10-Day Moving Average 10.94
    Average True Range 0.74
    RSI (14) 52.15
    ADX 15.32
    +DI 22.02
    -DI 17.78
    Chandelier Exit (Long, 3 ATRs) 10.52
    Chandelier Exit (Short, 3 ATRs) 11.46
    Upper Bollinger Bands 11.91
    Lower Bollinger Band 9.65
    Percent B (%b) 0.51
    BandWidth 20.91
    MACD Line 0.07
    MACD Signal Line 0.17
    MACD Histogram -0.0987
    Fundamentals Value
    Market Cap 618.9 Million
    Num Shares 57.3 Million
    EPS -3.81
    Price-to-Earnings (P/E) Ratio -2.84
    Price-to-Sales 0.00
    Price-to-Book 25.37
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 12.30
    Resistance 3 (R3) 12.17 11.56 12.05
    Resistance 2 (R2) 11.56 11.18 11.62 11.96
    Resistance 1 (R1) 11.18 10.94 11.37 11.31 11.88
    Pivot Point 10.57 10.57 10.66 10.63 10.57
    Support 1 (S1) 10.19 10.19 10.38 10.32 9.74
    Support 2 (S2) 9.58 9.95 9.64 9.66
    Support 3 (S3) 9.20 9.58 9.57
    Support 4 (S4) 9.33